TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8933676

Group type: EXPERIMENTAL
Intervention: Hb AS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hb AC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hb AA
Number of subjects: 30
Study: 2053092

Group type: EXPERIMENTAL
Intervention: Group meetings with families (4 to 40 at a time)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open communication with families by highly qualified physicians
Number of subjects: 0
Study: 6151492

Group type: EXPERIMENTAL
Intervention: Indalpine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 30879774

Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry
Number of subjects: 74

Group type: COMPARATOR
Intervention: Electric pulp test
Number of subjects: 74

Group type: COMPARATOR
Intervention: Ethyl chloride
Number of subjects: 74
Study: 30416635

Group type: COMPARATOR
Intervention: Epidural Block
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Transverse Abdominis Plane (TAP) Block
Number of subjects: 80
Study: 26946731

Group type: EXPERIMENTAL
Intervention: Dog days plaster (acupoint application)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo (buckwheat plaster without medical ingredient)
Number of subjects: 249
Study: 24969712

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Routine therapy with HFCWO
Number of subjects: 35
Study: 22268427

Group type: EXPERIMENTAL
Intervention: Fractional 1,550-nm Yb/Er fiber laser
Number of subjects: 22

Group type: COMPARATOR
Intervention: Variable square pulse 2,940-nm Er:YAG laser
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 22
Study: 19702465

Group type: EXPERIMENTAL
Intervention: Parkinson's disease (PD) group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups (PD and healthy controls)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Motor symptom severity in PD patients
Number of subjects: 52
Study: 17405901

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus bevacizumab (10 mg/kg, i.v. infusion on day 1, every 2 weeks)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus bevacizumab
Number of subjects: 829

Group type: COMPARATOR
Intervention: FOLFOX4 alone
Number of subjects: 829
Study: 16762801

Group type: EXPERIMENTAL
Intervention: Big endothelin-1 (Big ET-1)
Number of subjects: 2359
Study: 12486422

Group type: EXPERIMENTAL
Intervention: Cpn IgA > or =1:32
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Cpn IgA > or =1:16
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Cpn IgA > or =1:64
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Cpn IgA > or =1:128
Number of subjects: 178

Group type: COMPARATOR
Intervention: Cpn IgG
Number of subjects: 178
Study: 10453433

Group type: EXPERIMENTAL
Intervention: Intervention group (187 patients) with systematic lipid assessment and active pharmacologic lipid therapy.
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group (51 patients) with no systematic lipid lowering intervention.
Number of subjects: 238
Study: 8542224

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 20

Group type: COMPARATOR
Intervention: No fibrin sealant
Number of subjects: 20
Study: 2675597

Group type: EXPERIMENTAL
Intervention: Strict diabetic protocol (diet and insulin therapy)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Untreated group (baseline capillary blood glucose testing)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Treated group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (normal oral glucose tolerance test)
Number of subjects: 126
Study: 322251

Group type: EXPERIMENTAL
Intervention: Dissolvent tablets containing mixed enzyme preparations
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dissolvent tablets containing pure enzymes
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 100

Group type: COMPARATOR
Intervention: Steradent tablets
Number of subjects: 100
Study: 30105946

Group type: EXPERIMENTAL
Intervention: App-based self-teaching course
Number of subjects: 165

Group type: COMPARATOR
Intervention: Instructor-led course
Number of subjects: 165
Study: 29268061

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 50
Study: 26356402

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 60
Study: 23637967

Group type: EXPERIMENTAL
Intervention: 1 mg CPG 7909 as adjuvant
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo-adjuvant
Number of subjects: 68
Study: 21991704

Group type: EXPERIMENTAL
Intervention: Cooled lignocaine gel (4 degrees C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Room temperature lignocaine gel (20 degrees C)
Number of subjects: 60
Study: 19189349

Group type: EXPERIMENTAL
Intervention: Complete resection (group A)
Number of subjects: 3126

Group type: COMPARATOR
Intervention: Small residual tumor burden of 1-10 mm (group B)
Number of subjects: 3126

Group type: COMPARATOR
Intervention: Macroscopic residual disease exceeding 1 cm (group C)
Number of subjects: 3126
Study: 16456657

Group type: EXPERIMENTAL
Intervention: Nicotine (12 microg/kg body weight)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 33
Study: 14683737

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 2180
Study: 16750781

Group type: EXPERIMENTAL
Intervention: Endothelium-dependent vasodilation (EDV)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Endothelium-independent vasodilation (EIV)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EDV response of 8%
Number of subjects: 75
Study: 10562823

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg body weight over 3 days) + Primaquine (15 mg daily for 14 days)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Chloroquine (25 mg base/kg body weight over 3 days)
Number of subjects: 886
Study: 7575779

Group type: EXPERIMENTAL
Intervention: Cyclosporin (cyA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Prednisolone and azathioprine
Number of subjects: 66
Study: 1686131

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.5 mg/h
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Flumazenil 0.1 mg/h
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 7272160

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Oxprenolol 80 mg
Number of subjects: 7
Study: 31470806

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gastric distension
Number of subjects: 10
Study: 30171752

Group type: EXPERIMENTAL
Intervention: Intrarectal local anesthesia (IRLA)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block anesthesia (PPNB)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control (blank)
Number of subjects: 253
Study: 27249891

Group type: EXPERIMENTAL
Intervention: 7-point SMBG
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: 5-point SMBG
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 191
Study: 25295719

Group type: COMPARATOR
Intervention: PCIA with morphine (M group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCIA with tramadol (T group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCIA with tramadol combined with lornoxicam (L group)
Number of subjects: 60
Study: 22777991

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate (80 mg of elemental iron daily)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 20456306

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 17563739

Group type: EXPERIMENTAL
Intervention: Interleukin 2 (IL-2) at 1 million units/m² SQ daily for 28 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) at 1.25 mg/kg intravenously daily from day 0 to +28 and interferon gamma (IFN-gamma) 0.025 mg/m² SQ every 2 days from day +7 to +28
Number of subjects: 72
Study: 15712603

Group type: EXPERIMENTAL
Intervention: Histamine releasing test (HRT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interferon (INF)-gamma releasing test
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CellScan test (CST)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Histamine releasing test (HRT) for high suspicion level drugs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interferon (INF)-gamma releasing test for high suspicion level drugs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CellScan method for high suspicion level drugs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Histamine releasing test (HRT) for low suspicion level drugs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Interferon (INF)-gamma releasing test for low suspicion level drugs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CellScan method for low suspicion level drugs
Number of subjects: 21

Group type: COMPARATOR
Intervention: CellScan method (CST) in controls
Number of subjects: 21
Study: 11870013

Group type: EXPERIMENTAL
Intervention: Nortriptyline and interpersonal psychotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nortriptyline and clinic visits
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo and psychotherapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo and clinic visits
Number of subjects: 49
Study: 10097871

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative treatment options (including psychopharmacology)
Number of subjects: 0
Study: 8668449

Group type: EXPERIMENTAL
Intervention: Supervised walking group
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nonwalking group
Number of subjects: 27
Study: 2403654

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (100 mg/kg/day, intravenously once daily; n = 53)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cefuroxime (240 mg/kg/day, intravenously in four equal doses; n = 53)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 106

Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 106
Study: 31143952

Group type: COMPARATOR
Intervention: Conventional protocol (2 × 180 s per vein)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TTI-guided approach (TTI + 120 s per vein or 1 × 180 s if TTI could not be measured)
Number of subjects: 70
Study: 29878691

Group type: EXPERIMENTAL
Intervention: Patient-centered self-management empowerment intervention (PCSMEI)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 144
Study: 27080652

Group type: EXPERIMENTAL
Intervention: Deactivated indiscriminable electrodes for a minimum of 2 months
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Deactivated discriminable electrodes
Number of subjects: 13

Group type: COMPARATOR
Intervention: Optimised clinical maps
Number of subjects: 13
Study: 25442042

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with oxaliplatin (130 mg/m² on day 1) and capecitabine (1000 mg/m² twice daily for 14 days every 3 weeks), followed by chemoradiation therapy (50 Gy over 5 weeks with modified XELOX regimen), and then consolidation chemotherapy with XELOX regimen.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Neoadjuvant sandwich treatment using XELOX regimen as induction, concomitant, and consolidation chemotherapy.
Number of subjects: 51
Study: 22071420

Group type: EXPERIMENTAL
Intervention: ZnCl2 2.5mM
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ZnCl2 5mM
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ZnCl2 10mM
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ZnCl2 20mM
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (Double Distilled Water)
Number of subjects: 9
Study: 20651221

Group type: EXPERIMENTAL
Intervention: G0 (glucose ingested at onset of cold exposure)
Number of subjects: 0

Group type: COMPARATOR
Intervention: G60 (glucose ingested after 60 min of cold exposure)
Number of subjects: 0
Study: 19357442

Group type: EXPERIMENTAL
Intervention: Doxepin, 10 mg, twice a day for 1 week
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15167462

Group type: EXPERIMENTAL
Intervention: Cold temperatures applied to enamel using tetrafluoroethane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cold temperatures applied to enamel
Number of subjects: 18
Study: 12068838

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid
Number of subjects: 11
Study: 9839759

Group type: EXPERIMENTAL
Intervention: Donepezil HCl 1 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Donepezil HCl 3 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Donepezil HCl 5 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Donepezil HCl (all doses)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7806692

Group type: EXPERIMENTAL
Intervention: Gepirone (10 mg capsules, thrice daily, up to 120 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 2760597

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief dynamic therapy
Number of subjects: 0
Study: 331830

Group type: EXPERIMENTAL
Intervention: Intra-nasal beclomethasone dipropionate
Number of subjects: 92
Study: 31984781

Group type: EXPERIMENTAL
Intervention: Low intentions to complete the study
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: High intentions to complete the study
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Income level
Number of subjects: 316
Study: 31384338

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg IV)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Ondansetron (8 mg IV)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Tropisetron (5 mg IV)
Number of subjects: 165
Study: 26968329

Group type: EXPERIMENTAL
Intervention: Verbal working memory training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 36
Study: 27097485

Group type: EXPERIMENTAL
Intervention: Malaria control knowledge awareness
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Media as a source of information
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Sex, area, and education levels
Number of subjects: 800

Group type: COMPARATOR
Intervention: Country vs Urban students
Number of subjects: 800

Group type: COMPARATOR
Intervention: Secondary vs Primary school students
Number of subjects: 800
Study: 23992935

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 2 g/day
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 20336302

Group type: EXPERIMENTAL
Intervention: 0.2 mg of tamsulosin daily for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tamsulosin after cessation of therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo after cessation of therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tamsulosin and placebo groups for peak urinary flow rate, PVR, and IIEF
Number of subjects: 100
Study: 18762647

Group type: EXPERIMENTAL
Intervention: Early weight-bearing
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-weight-bearing
Number of subjects: 110
Study: 16028524

Group type: EXPERIMENTAL
Intervention: Pneumo‐23
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Act‐HIB
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not vaccinated)
Number of subjects: 38
Study: 11917292

Group type: COMPARATOR
Intervention: Pharmacologic agents developed to ameliorate or prevent toxicities (specific agents not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled, randomized phase II studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phase III studies of toxicity modifiers
Number of subjects: 0
Study: 10070911

Group type: EXPERIMENTAL
Intervention: High-dose i.v. sodium ferric gluconate complex in sucrose (1.0 g)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Low-dose i.v. sodium ferric gluconate complex in sucrose (0.5 g)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Oral iron treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (historically matched patients)
Number of subjects: 88
Study: 7588508

Group type: EXPERIMENTAL
Intervention: 80 g fat meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: 20 g fat meal
Number of subjects: 10
Study: 2188410

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam rectally
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1 g acetyl salicylic acid as effervescing tablets
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: All groups (diazepam, acetyl salicylic acid, placebo)
Number of subjects: 94
Study: 6160032

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 20
Study: 31948926

Group type: EXPERIMENTAL
Intervention: Three-variable model (IL-8, bicarbonate, protein C)
Number of subjects: 2737

Group type: EXPERIMENTAL
Intervention: Four-variable model (IL-8, bicarbonate, protein C, vasopressor use)
Number of subjects: 2737

Group type: EXPERIMENTAL
Intervention: Hyperinflammatory phenotype
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Simvastatin treatment in HARP-2
Number of subjects: 2737
Study: 29371130

Group type: EXPERIMENTAL
Intervention: OLA-iCPAP
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: OLA-CPAP
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: STD-CPAP
Number of subjects: 967

Group type: COMPARATOR
Intervention: STD-O2
Number of subjects: 967
Study: 27577978

Group type: EXPERIMENTAL
Intervention: PEEK cage (group A, n=34)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Autologous cage using lumbar spinous process and laminae (ACSP, group B, n=35)
Number of subjects: 69
Study: 25122642

Group type: EXPERIMENTAL
Intervention: 8 mg of intravenous dexamethasone
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 23512440

Group type: EXPERIMENTAL
Intervention: 0.9 mg/m2 beloranib
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 20666328

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microg x kg(‐1) + ketamine 0.5 mg x kg(‐1) + fentanyl 1.0 microg x kg(‐1) + atropine 0.5 mg (group FNT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 microg x kg(‐1) + ketamine 0.5 mg x kg(‐1) + alfentanil 5.0 microg x kg(‐1) + atropine 0.5 mg (group ALFNT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pethidine 1.0 mg x kg(‐1) + atropine 0.5 mg (group Dolsin)
Number of subjects: 47
Study: 17148931

Group type: COMPARATOR
Intervention: Constant Continuous Positive Airway Pressure (CPAP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Automatic Continuous Positive Airway Pressure (APAP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 20
Study: 15925053

Group type: EXPERIMENTAL
Intervention: Mucoadhesive vaginal gel (MVG, Miphil) 2.5 g daily for the first week and then every 3 days for 5 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mucoadhesive vaginal gel (MVG, Miphil)
Number of subjects: 45
Study: 14700450

Group type: EXPERIMENTAL
Intervention: Controlled-release formulations of bupropion, paroxetine, and venlafaxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release formulations of bupropion, paroxetine, and venlafaxine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine (controlled-release)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine (immediate-release)
Number of subjects: 0
Study: 10552270

Group type: EXPERIMENTAL
Intervention: 15-kg load carriage
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 20-kg load carriage
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 15-kg and 20-kg load carriage
Number of subjects: 22
Study: 9505937

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8472631

Group type: EXPERIMENTAL
Intervention: Support group participation (facilitated by investigator and diabetic nurse specialist, met fortnightly for 6 months)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no participation in support group)
Number of subjects: 61
Study: 3523792

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZ) 50 mg twice daily
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cimetidine (CM) 400 mg twice daily
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZ) 50 mg at night (maintenance)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Cimetidine (CM) 400 mg at night (maintenance)
Number of subjects: 67
Study: 30115945

Group type: EXPERIMENTAL
Intervention: Placebo-IF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo-EF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control-IF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control-EF
Number of subjects: 60
Study: 27299418

Group type: EXPERIMENTAL
Intervention: Screw fixation
Number of subjects: 27

Group type: COMPARATOR
Intervention: No screw fixation (Control)
Number of subjects: 27
Study: 24664793

Group type: EXPERIMENTAL
Intervention: Claims-based measure of antipsychotic polypharmacy (90-day concurrent use of ≥2 antipsychotics, allowing for a 32-day gap)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Claims-based measure definitions tested
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Concordance between claims and medical record-based categorization
Number of subjects: 312
Study: 21722188

Group type: COMPARATOR
Intervention: Submerged healing (S)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Transmucosal healing (TM)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Both groups (S and TM)
Number of subjects: 127